Medipharm Labs Corp faced a significant downturn in its stock price, reflecting broader challenges in the cannabis sector.
In yesterday's trading session, Medipharm Labs Corp (LABS.TO) saw its stock price decline by 6.67%, closing at CA$0.07. This drop highlights ongoing struggles within the company and the cannabis industry, raising concerns for investors about its future viability.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$29.90M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.85
Analyst Price Targets
Based on analyst covering LABS · as of Sep 17, 2026
Wall Street analysts forecast LABS stock price to rise 42.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+42.9% Upside
Current Price
C$0.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
61.1%
Annualized
90-Day Vol
73.7%
Annualized
Trend (90d)
-29.0%
Annualized drift
90d Mean
C$0.06
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.07 | C$0.05 – C$0.08 |
| 60 trading days | C$0.07 | C$0.05 – C$0.09 |
| 90 trading days | C$0.06 | C$0.04 – C$0.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious as Medipharm Labs continues to grapple with profitability challenges and market volatility, particularly in the cannabis sector.
Stock Plummets 6.67%
Medipharm Labs Corp's market cap now sits at approximately CA$29.9 million, reflecting investor concerns over its financial health.
Bull case
If Medipharm Labs can take advantage of opportunities in the U.S. market and improve its operations, there may be potential for recovery in the long term.
Bear case
The company’s ongoing financial struggles and the absence of recent positive news could further erode investor confidence, leading to continued declines in its stock price.
Market Performance Overview
Advertisement
Yesterday, Medipharm Labs Corp's stock price fell by 6.67%, marking a significant downturn for the company. This decline is concerning given the company's previous struggles with profitability and market positioning. Investors are left questioning the sustainability of its business model in a competitive landscape.
Challenges Ahead
With a market cap of approximately CA$29.9 million, Medipharm Labs faces significant hurdles. The lack of recent positive news and ongoing financial challenges may deter potential investors. The company's future hinges on its ability to navigate these issues and capitalize on emerging opportunities in the U.S. market.
Looking Forward
As Medipharm Labs prepares to report its full year and fourth quarter financial results, investors will be closely monitoring the outcomes. Any signs of recovery or strategic pivots could influence market sentiment and potentially reverse the current downward trend.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
